Abstract: The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis, metastasis, tumorigenesis, cell migration, cell mobility in extracellular matrix and cell growth in extracellular matrix, and the factor is a polypeptide comprising an amino acid sequence according to SEQ ID. NO. 1 or a polypeptide having a sequence according to databank entries gi 9506687 or NP_061931, preferably NP_061931.1.
Type:
Application
Filed:
October 20, 2003
Publication date:
October 26, 2006
Applicant:
ATUGEN AG
Inventors:
Anke Klippel-Giese, Joerg Kaufmann, Rolf Schwarzer
Abstract: The present invention is related to the use of a ribonucleic acid for the manufacture of a medicament, wherein the ribonucleic acid comprises a double-stranded structure and the double-stranded structure comprises a first and a second strand, wherein the first strand comprises a first stretch of contiguous nucleotides and the second strand comprises a second stretch of contiguous nucleotides, wherein the first stretch is not complementary to a nucleic acid, preferably a mRNA, of a cell of an organism to be treated with said medicament and/or wherein the second stretch is different from a nucleic acid, preferably a mRNA of a cell of an organism to be treated with said medicament.
Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
Type:
Application
Filed:
August 5, 2003
Publication date:
September 16, 2004
Applicant:
Atugen AG
Inventors:
Klaus Giese, Jorg Kaufmann, Anke Klippel-Giese
Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.